Lidocaine for Oxaliplatin-induced Neuropathy
Intravenous Lidocaine for Preventing Painful Oxaliplatin-induced Peripheral Neuropathy (OIPN)
Sponsor: Washington University School of Medicine
This PHASE1/PHASE2 trial investigates Chemotherapy-induced Peripheral Neuropathy and Colorectal Cancer and is currently completed. Washington University School of Medicine leads this study, which shows 13 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
May 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 8 earlier versions
-
Feb 2021 — May 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2020 — Jun 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2019 — Feb 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .